Effect of Bergamot Juice on LDL Cholesterol Level in Healthy Subjects
NCT ID: NCT05589636
Last Updated: 2022-10-21
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
NA
44 participants
INTERVENTIONAL
2022-02-10
2023-07-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Bergamot and Cardio-Metabolic Risk Factors
NCT02205567
Evaluation of the Hypolipidemic Effect of Bergavit by a Human Trial.
NCT06692777
The Effects of Orange Juice on Plasma Lipids
NCT01350843
Effects of Regular and Consequent Citrus Fruits Consumption on Vascular Protection
NCT00539916
The Impact of Citrus Products on Cardiovascular Health
NCT03611114
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
PREVENTION
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Bergamot juice
Consumption of 400 cc/die of Bergamot juice (35% in water sweetened with stevia) for 12 weeks
Bergamot Juice
Bergamot Juice (35% in water)
Free diet
Free diet
No interventions assigned to this group
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Bergamot Juice
Bergamot Juice (35% in water)
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* ability to understand the methods, purposes and implications of the study, and to give free and informed consent
Exclusion Criteria
* Present or past history of alcohol or drug abuse or organ failure (kidney and liver)
* Tumor pathologies in the last 5 years;
* Past or present cerebro-vascular diseases;
* Subjects taking drugs or supplements active on the lipid profile;
* Pregnancy or breastfeeding
* Presence of severe or monogenic dyslipidemia
* Use of antibiotics in the last three months before enrollment
* Subjects who are on a diet for any reason
* Individuals who have intentionally or unintentionally lost 3 kg or more of body weight in the past 3 months.
* Known allergies to some components of the product
* Subjects who do not like bergamot
18 Years
75 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
University of Parma
OTHER
Azienda Ospedaliero-Universitaria di Parma
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Alessandra Dei Cas
Associate Professor
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
University of Parma, Department of Medicine and Surgery
Parma, , Italy
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
References
Explore related publications, articles, or registry entries linked to this study.
Ballistreri G, Amenta M, Fabroni S, Consoli V, Grosso S, Vanella L, Sorrenti V, Rapisarda P. Evaluation of lipid and cholesterol-lowering effect of bioflavonoids from bergamot extract. Nat Prod Res. 2021 Dec;35(23):5378-5383. doi: 10.1080/14786419.2020.1768085. Epub 2020 May 22.
Cappello AR, Dolce V, Iacopetta D, Martello M, Fiorillo M, Curcio R, Muto L, Dhanyalayam D. Bergamot (Citrus bergamia Risso) Flavonoids and Their Potential Benefits in Human Hyperlipidemia and Atherosclerosis: an Overview. Mini Rev Med Chem. 2016;16(8):619-29. doi: 10.2174/1389557515666150709110222.
Di Donna L, De Luca G, Mazzotti F, Napoli A, Salerno R, Taverna D, Sindona G. Statin-like principles of bergamot fruit (Citrus bergamia): isolation of 3-hydroxymethylglutaryl flavonoid glycosides. J Nat Prod. 2009 Jul;72(7):1352-4. doi: 10.1021/np900096w.
Ference BA, Ginsberg HN, Graham I, Ray KK, Packard CJ, Bruckert E, Hegele RA, Krauss RM, Raal FJ, Schunkert H, Watts GF, Boren J, Fazio S, Horton JD, Masana L, Nicholls SJ, Nordestgaard BG, van de Sluis B, Taskinen MR, Tokgozoglu L, Landmesser U, Laufs U, Wiklund O, Stock JK, Chapman MJ, Catapano AL. Low-density lipoproteins cause atherosclerotic cardiovascular disease. 1. Evidence from genetic, epidemiologic, and clinical studies. A consensus statement from the European Atherosclerosis Society Consensus Panel. Eur Heart J. 2017 Aug 21;38(32):2459-2472. doi: 10.1093/eurheartj/ehx144.
Silverman MG, Ference BA, Im K, Wiviott SD, Giugliano RP, Grundy SM, Braunwald E, Sabatine MS. Association Between Lowering LDL-C and Cardiovascular Risk Reduction Among Different Therapeutic Interventions: A Systematic Review and Meta-analysis. JAMA. 2016 Sep 27;316(12):1289-97. doi: 10.1001/jama.2016.13985.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
562/2021/SPER /UNIPR
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.